Search
Isotretinoin
go.drugbank.com/drugs/DB00982ApprovedInvestigationalIsotretinoin is a retinoid derivative of vitamin A used in the treatment of severe recalcitrant acne. … [L6574] Isotretinoin is associated with major risks in pregnancy and is therefore only available under the iPLEDGE program in the United States.
Mixtures: ISOTREXIN JEL, 30 G, ETREXİN % 2 + % 0.05 JELCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesFomivirsen
go.drugbank.com/drugs/DB06759ApprovedWithdrawnAs a complementary nucleotide to the messenger RNA of the major immediate-early region proteins of human cytomegalovirus, it disrupts the replication of the virus through an antisense mechanism [L1428] … Fomivirsen is marketed under the trade name Vitravene for intravitreal injection and was the first antisense drug to be approved by the Food and Drug Administration (FDA).
Categories: Compounds used in a research, industrial, or household settingCinnamyl alcohol
go.drugbank.com/drugs/DB14186ApprovedCinnamyl alcohol has been shown to be a skin sensitizer, with a NOEL (No Effect Level) of ~4% [A34266]. Sensitivity to cinnamyl alcohol may be identified with a clinical patch test. … Due to the low levels found in cinnamon, cinnamyl alcohol is usually supplied as [DB14184] within commercial products.
Synonyms: (2E)-3-phenylprop-2-en-1-ol, (E)-cinnamyl alcoholErdosteine
go.drugbank.com/drugs/DB05057ApprovedInvestigationalIt is a _thiol_ derivative produced for the clinical management of chronic obstructive bronchitis, in addition to infective exacerbations of chronic bronchitis. … Erdosteine is a drug that causes a breakdown of mucus, also known as a _mucolytic_ agent.
Categories: Heterocyclic Compounds, 1-RingProducts: DOSTEIN® CAPSULAS, DOSTEIN® SUSPENSIONPegzilarginase
go.drugbank.com/drugs/DB14780ApprovedPegzilarginase is a recombinant, cobalt-substituted, and pegylated human arginase 1 enzyme therapy designed to address the underlying metabolic deficit in arginase 1 deficiency (ARG1-D). … FDA in February 2026 for the treatment of hyperargininemia in adult and pediatric patients aged 2 years and older with ARG1-D, to be used in conjunction with dietary protein restriction.
Synonyms: Optimised human arginase I, Co-ArgI-PEG modified human arginase IMirvetuximab soravtansine
go.drugbank.com/drugs/DB12489ApprovedInvestigational[A254392,L43967] DM4 is conjugated to the antibody with a drug-to-antibody ratio of 3.5:1. … linker to the genotoxic compound DM4 (also known as soravtansine or ravtansine).
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesOteseconazole
go.drugbank.com/drugs/DB13055ApprovedInvestigational[L41635] CYP51, also known as 14α demethylase, participates in the formation of ergosterol, a compound that plays a vital role in the integrity of cell membranes. … [A247035] This is possible thanks to the tetrazole moiety in oteseconazole that increases target selectivity.
Categories: Heterocyclic Compounds, 1-RingSynonyms: (R)-2-(2,4-difluorophenyl)-1,1-difluoro-3-(1H-tetrazol-1-yl)-1(5-(4-(2,2,2-trifluoroethoxy)phenyl)pyridin-2-yl)propan-2-ol, 2-Pyridineethanol, α-(2,4difluorophenyl)-β β-difluoro- α-(1H-tetrazol-1-ylmethyl)-5-(4-(2,2,2-trifluoroethoxy)phenyl)-,(αR)Moroctocog alfa
go.drugbank.com/drugs/DB13999ApprovedMoroctocog alfa is approved by Health Canada and by the European Medicines Agency for the control and prevention of hemorrhagic episodes and for routine and surgical prophylaxis in patients with hemophilia … Also known as Anti-Hemophilic Factor (AHF), endogenous Factor VIII is essential to the clotting process in the body due to its involvement in the clotting cascade where it is responsible for acting as
Synonyms: B-domain deleted recombinant factor VIII, Human factor VIII, recombinant B-domain deletedProducts: REFACTO AF 500 IU IV ENJEKSIYONLUK COZELTI ICIN TOZ VE COZUC FLAKON, 1 ADET, REFACTO AF 250 IU IV ENJEKSIYONLUK COZELTI ICIN TOZ VE COZUCU FLAKON, 1 ADETDanicopan
go.drugbank.com/drugs/DB15401ApprovedInvestigational[A263501,L50411] Danicopan is a small molecule complement factor D inhibitor that selectively blocks the alternative pathway, thereby working to address extravascular hemolysis when used in conjunction … [L50381] It was first approved in January 2024 in Japan for patients with PNH,[A263506,L50416] shortly after which the EMA adopted a positive opinion and recommended granting it marketing authorization
Categories: P-glycoprotein inhibitors, Complement Factor D InhibitorSynonyms: (2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide, (2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidine-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridine-2-yl)-4-fluoropyrrolidine-2-carboxamideLodoxamide
go.drugbank.com/drugs/DB06794ApprovedLodoxamide is a mast-cell stabilizer for topical administration into the eye. … Lodoxamide is marketed under the brand name Alomide by Alcon.
Synonyms: N,N'-(2-chloro-5-cyano-m-phenylene)dioxamateProducts: THILOMIDE GÖZ DAMLASI, 5 ML, ALOMİDE % 0.1 GÖZ DAMLASI, ÇÖZELTİ, 5 ML